AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01064583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cocoa
Description: dissolved in water twice-daily intervention
Study NCT02971891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS006 (Furosemide) Topical Gel
Study NCT02971891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Study NCT02929342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Study NCT02929342 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]-Pitolisant
Study NCT05153278 — intervention group
Intervention type: BIOLOGICAL
Intervention: Packed red blood cells
Description: Standard treatment for iron deficiency anemia (control)
Study NCT05153278 — intervention group
Intervention type: DRUG
Intervention: Intravenous drug
Description: Experimental treatment for iron deficiency treatment
Study NCT02774343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
Study NCT02774343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
Study NCT02774343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Cognitive-behavioral therapy 1 hour per week
Study NCT02774343 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Cognitive-behavioral therapy 1 hour per week
Study NCT02774343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Prize-based contingency management for attendance
Study NCT02774343 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: Prize-based contingency management for attendance
Study NCT03477461 — intervention group
Intervention type: DRUG
Intervention: terlipressin
Description: a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
Study NCT06273189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional
Description: In conventional group, contralateral side mandibular osteotomies were performed with Lindeman and round bur (Karl Storz, Tuttlingen, Germany)
Study NCT06273189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scalpel
Description: In ultrasonic device group, osteotomies one side of the mandible were performed unilaterally using an ultrasonic bone scalpel (BoneScalpel; Misonix, Farmingdale, NY) with a serrated standard blade
Study NCT01705470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Study NCT01705470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo normal saline
Study NCT03692988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
Study NCT02173535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant AP
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
Study NCT02173535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant JG
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
Study NCT02173535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant CS
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
Study NCT02173535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant VC
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
Study NCT02173535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant LA
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
Study NCT04329052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adventure-based training with health educational talk
Description: Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
Study NCT04005547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder
Description: Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication \*Bring your Trusted Adult\* Session 6 - Let's Talk About Growing Up
Study NCT00926965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride
Description: amisulpride tablet 100-1200mg/day for 24 months
Study NCT00926965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine tablet 2.5 to 30 mg/day for 24 months
Study NCT00926965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional antipsychotics
Description: the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
Study NCT04579393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fostamatinib
Description: The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
Study NCT02936154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Study NCT02936154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02682498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Bupivacaine Liposome Injectable Suspension)
Description: Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
Study NCT02682498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation
Description: A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
Study NCT04316767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Intervention
Description: Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
Study NCT00242463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone (anabolic steroid)
Study NCT00242463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04594434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scale SUD
Description: Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
Study NCT04594434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scale SUD
Description: Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
Study NCT03317210 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: iron sucrose (200 mg VENOFER®)
Description: According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.
Study NCT03317210 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: recombinant human erythropoietin (10,000 U EPREX®)
Description: According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
Study NCT02453087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCDS0780A
Description: Participants will receive escalating doses of DCDS0780A as intravenous infusion.
Study NCT02453087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion.
Study NCT02453087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
Study NCT04594434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VOC scale
Description: The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
Study NCT04594434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOC scale
Description: The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
Study NCT04594434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DES II scale
Description: The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
Study NCT04594434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DES II scale
Description: The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
Study NCT00469898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~\*up to 6 cycles at physician's discretion
Study NCT00469898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes.
Study NCT03499873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3% Oph Susp
Description: Nepafenac 0.3% Ophthalmic suspension (experimental product)
Study NCT03499873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT03499873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.3% Oph Susp (reference)
Description: Nepafenac 0.3% Ophthalmic suspension (Innovator)
Study NCT01055834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Description: Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting >=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast \& the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration.
Study NCT01055834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 1 mg
Description: Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug.
Study NCT00728754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant Osseotite Prevail
Description: Root form titanium dental implant
Study NCT00728754 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant Osseotite
Description: root form titanium dental implant
Study NCT04021511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OAR application by a nurse
Description: As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
Study NCT02654145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100mg SC
Description: At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
Study NCT02654145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol MDIs
Description: Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
Study NCT02654145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
Study NCT02253329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein plus NMES during the day
Description: Neuromuscular electrical stimulation after a protein bolus, performed during the day
Study NCT02253329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein plus NMES prior to sleep
Description: Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
Study NCT02856594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine
Study NCT02856594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02325232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy, double balloon enteroscopy sequential use
Description: Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
Study NCT04323709 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
Study NCT04323709 — intervention group
Intervention type: OTHER
Intervention: Data analysis
Description: Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
Study NCT00872469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1-2 grams by intravenous injection
Study NCT00872469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo [Saline]
Description: Matched to active comparator
Study NCT01349907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
Study NCT01349907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam \[up to 4 mg/day\] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Study NCT04313348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eMobilize-Uganda application
Description: Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period.
Study NCT04313348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMobilize-Uganda application
Description: Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period.
Study NCT02269319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-I
Description: Oral MRX-I 800mg given twice a day for 10 days
Study NCT02269319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Oral linezolid 600mg given twice a day for 10 days
Study NCT02665962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Perioperative Caloric Restriction Program
Study NCT02120872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin and simvastatin
Description: Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
Study NCT02120872 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Platelet rich fibrin
Description: Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
Study NCT02120872 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open Flap Debridement alone
Description: Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.